Sanofi Snaps Up Bioverativ for $11.6B, Boosting Hemophilia and Rare Disease Offerings

Sanofi Snaps Up Bioverativ for $11.6B, Boosting Hemophilia and Rare Disease Offerings  Genetic Engineering & Biotechnology News Sanofi beefs up pipeline with $11B Bioverativ buy  BioPharma Dive Sanofi shells out $11.6bn on Bioverativ  PharmaTimesFull coverage